Your institution may have access to this item. Find your institution then sign in to continue.
Title
Immunotherapy Plus VEGF Inhibitor Added to TACE Improves PFS in Unresectable HCC.
Abstract
The article focuses on the efficacy of combining durvalumab and bevacizumab with transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC), emphasizing its significant improvement in progression-free survival (PFS). Topics discussed include the results of the Emerald-1 trial, the rationale for combining immunotherapy with TACE, and the manageable safety profile of the combination therapy.